IL-5[Biotinylated]:IL-5Rα Inhibitor Screening ELISA Kit
Background/背景
Interleukin (IL)-5 is produced and secreted by T cells and mast cellsa critical,and is the important regulator of eosinophils and a therapeutic target for asthma. The pharmaceutical inhibition of IL-5 has been shown to reduce eosinophil counts and ameliorate asthmatic symptoms in studies on animal models of allergy as well as in human clinical trials. There are currently three commercially available IL-5 inhibitors in the United States. These include reslizumab (trade name Cinqair), benralizumab (trade name Fasenra), and mepolizumab (trade name Nucala). All three medications have been approved by the FDA for the treatment of severe eosinophilic asthma.
Assay Principles/原理
This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new IL-5 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human IL-5 to immobilized human IL-5 R alpha in a functional ELISA assay, and employs a simple colorimetric sandwich ELISA platform.
Your experiment will include 4 simple steps:
a) Coat the plate with human IL-5 R alpha.
b) Add your molecule of interest to the tests.
c) Add human IL-5-Biotin to bind the coated human IL-5 R alpha.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
e) Finally, the ability of your compound to inhibit IL-5: IL-5 R alpha Rbinding will be determined by comparing OD readings among different experimental groups.
Application/應用
This kit is developed for screening for inhibitors of human IL-5Rα binding to human IL-5.
It is for research use only.
Reconstitution/重構方法
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage/存儲
The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
關鍵字： IL-5 ELISA Kit;IL-5試劑盒;IL-5 ELISA試劑盒;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。